In this slide show we highlight some of the top news on lung cancer in 2017, including FDA approvals, a new standard of care for ALK-positive lung cancer, increased risk with vitamin B supplements, and more.
Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC
Surufatinib/toripalimab elicited an ORR of 57.1% in patients with treatment-naïve NSCLC and 15.8% in patients with pretreated SCLC in a phase 2 trial.
Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs
Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC
An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.
Achieving Health Equity in Lung Cancer Surgery
Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.
Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer
Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.
AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer
The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.